Agios Pharmaceuticals (AGIO) Stock
Mid-cap biotech developing metabolism treatments for rare diseases. Here's the price, business snapshot, and what's worth knowing about Agios Pharmaceuticals in October 2026.
Agios Pharmaceuticals (AGIO) is a US biotechnology company focused on therapies that target cellular metabolism, with programmes in oncology and rare genetic diseases. Investors should know this is a pipeline-driven business: value depends heavily on clinical-trial results, regulatory decisions and any commercial uptake of approved medicines. The company has product revenues alongside R&D spending and may pursue partnerships and licensing to broaden reach. With a market capitalisation near $2.52 billion, Agios sits in the mid-cap biotech range — offering meaningful upside if development milestones succeed, but also notable downside if trials fail or approvals are delayed. Expect volatility, ongoing cash burn while R&D continues, and periodic binary events that can move the share price. This summary is educational, not personalised investment advice; consider your risk tolerance and time horizon and consult a financial adviser before acting.
Agios Pharmaceuticals (AGIO) Stock Forecast
Analyst price target, next 12 months
$50.18
+57.8% vs today's $31.81
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Agios Pharmaceuticals have a consensus 12-month target of $50.18, above the current price of $31.81.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 11 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Agios Pharmaceuticals' stock with a target price of $50.18, indicating growth potential.
Financial Health
AGIOS Pharmaceuticals is performing well with strong profits and cash flow, indicating solid financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical trial readouts and approvals can rapidly change valuation, offering potential upside while also creating volatility from binary outcomes.
Innovative Science
A focus on metabolic targets differentiates Agios, but long and costly R&D means results are uncertain and timelines can shift.
Commercial Upside
Approved products and partnerships can provide revenue and validation, though market uptake and competition may limit returns.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
